Skip to main content
Erschienen in:

01.06.2007 | Leitthema

Hochdosischemotherapie beim Mammakarzinom

verfasst von: Dr. P. Schmid

Erschienen in: Die Onkologie | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Weder in der adjuvanten noch in der palliativen Behandlungssituation konnte bisher eine klare Überlegenheit der Hochdosischemotherapie (HDCT) gegenüber den bestmöglichen konventionellen Therapien nachgewiesen werden. Für die adjuvante Therapie zeigte lediglich eine von 14 Studien einen signifikanten Überlebensvorteil nach HDCT, wobei am ehesten jüngere Frauen sowie Patientinnen mit ≥10 befallenen Lymphknoten oder Her2/neu-negativen Tumoren von einer HDCT profitieren. In der metastasierten Situation konnten zwar 4 von 6 Studien ein längeres progressionsfreies Überleben demonstrieren, ohne dass dies jedoch mit einem Überlebensvorteil einherging. Die Interpretation der bisherigen Studien wird durch geringe Fallzahlen, uneinheitliche und z. T. intensivierte konventionelle Behandlungsarme und den Einsatz ungeeigneter Zytostatika erschwert. Verschiedene Ansätze wie das Konzept der frühen Intensivierung sind nicht ausreichend untersucht. Bis zum Nachweis eines klaren Vorteils sollte in Anbetracht der erhöhten Morbidität und Mortalität der Einsatz der HDCT randomisierten Studien vorbehalten sein.
Literatur
1.
Zurück zum Zitat Basser R, O’Neill A, Martinelli G et al. (2003) Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15–95. Proc Am Soc Clin Oncol 22: Abstract 20 Basser R, O’Neill A, Martinelli G et al. (2003) Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15–95. Proc Am Soc Clin Oncol 22: Abstract 20
2.
Zurück zum Zitat Bergh J, Wiklund T, Erikstein B et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356: 1384–1391PubMedCrossRef Bergh J, Wiklund T, Erikstein B et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356: 1384–1391PubMedCrossRef
3.
Zurück zum Zitat Biron P, Durand M, Roche H (2002) High dose Thiotepa, cyclophosphamide and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: Results of the PEGASE 03 French Protocol. Proc Am Soc Clin Oncol 21: Abstract 168 Biron P, Durand M, Roche H (2002) High dose Thiotepa, cyclophosphamide and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: Results of the PEGASE 03 French Protocol. Proc Am Soc Clin Oncol 21: Abstract 168
4.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439PubMedCrossRef Citron ML, Berry DA, Cirrincione C et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439PubMedCrossRef
5.
Zurück zum Zitat Coombes RC, Howell A, Emson M et al. (2005) High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16: 726–734PubMedCrossRef Coombes RC, Howell A, Emson M et al. (2005) High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16: 726–734PubMedCrossRef
6.
Zurück zum Zitat Crump M, Gluck S, Stewart D (2001) A Randomized Trial Of High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Support Compared To Standard Therapy In Women With Metastatic Breast Cancer: A National Cancer Institute Of Canada (NCIC) Clinical Trials Group Study. Proc Am Soc Clin Oncol 2001: Abstract 82 Crump M, Gluck S, Stewart D (2001) A Randomized Trial Of High-Dose Chemotherapy With Autologous Peripheral Blood Stem Cell Support Compared To Standard Therapy In Women With Metastatic Breast Cancer: A National Cancer Institute Of Canada (NCIC) Clinical Trials Group Study. Proc Am Soc Clin Oncol 2001: Abstract 82
7.
Zurück zum Zitat Daly MB, Goldstein LJ, Topolsky D (2000) Quality of Life Experience in Women Rundomized to High-Dose Chemotherapy (HDC) und Stem Cell Support (SCT) or Stundard Dose Chemotherapy for Responding Metastatic Breast Cancer in Philadelphia Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 19: Abstract 327 Daly MB, Goldstein LJ, Topolsky D (2000) Quality of Life Experience in Women Rundomized to High-Dose Chemotherapy (HDC) und Stem Cell Support (SCT) or Stundard Dose Chemotherapy for Responding Metastatic Breast Cancer in Philadelphia Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 19: Abstract 327
8.
Zurück zum Zitat DeJonge ME, Huitema AD, Tukker AC et al. (2005) Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 11: 273–283CrossRef DeJonge ME, Huitema AD, Tukker AC et al. (2005) Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 11: 273–283CrossRef
9.
Zurück zum Zitat DeMichele A, Aplenc R, Botbyl J et al. (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23: 5552–5559PubMedCrossRef DeMichele A, Aplenc R, Botbyl J et al. (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23: 5552–5559PubMedCrossRef
10.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717CrossRef Early Breast Cancer Trialists‘ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717CrossRef
11.
Zurück zum Zitat Farquhar C, Marjoribanks J, Basser R et al. (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. The Cochrane Database of Systematic Reviews 2005, Issue 3 Farquhar C, Marjoribanks J, Basser R et al. (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. The Cochrane Database of Systematic Reviews 2005, Issue 3
12.
Zurück zum Zitat Farquhar C, Marjoribanks J, Basser R et al. (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. The Cochrane Database of Systematic Reviews 2005, Issue 3 Farquhar C, Marjoribanks J, Basser R et al. (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. The Cochrane Database of Systematic Reviews 2005, Issue 3
13.
Zurück zum Zitat Fossati R, Confalonieri C, Torri V (1998) Cytotoxic und hormonal treatment for metastatic breast cancer: a systematic review of published rundomized trials involving 31510 women. J Clin Oncol 16: 3439–3460PubMed Fossati R, Confalonieri C, Torri V (1998) Cytotoxic und hormonal treatment for metastatic breast cancer: a systematic review of published rundomized trials involving 31510 women. J Clin Oncol 16: 3439–3460PubMed
14.
Zurück zum Zitat Gianni A, Bonadonna G (2001) Five-Year Results Of The Randomized Clinical Trial Comparing Standard Versus High-Dose Myeloablative Chemotherapy In The Adjuvant Treatment Of Breast Cancer With >3 Positive Nodes (LN+). Proc Am Soc Clin Oncol: Abstract 80 Gianni A, Bonadonna G (2001) Five-Year Results Of The Randomized Clinical Trial Comparing Standard Versus High-Dose Myeloablative Chemotherapy In The Adjuvant Treatment Of Breast Cancer With >3 Positive Nodes (LN+). Proc Am Soc Clin Oncol: Abstract 80
15.
Zurück zum Zitat Greenberg PAC, Hortobagyi G, Smith T (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–205PubMed Greenberg PAC, Hortobagyi G, Smith T (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–205PubMed
16.
Zurück zum Zitat Hortobagyi GN, Buzdar AU, Theriault RL et al. (2000) Randomized trial of high-dose chemotherapy und blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92: 225–233PubMedCrossRef Hortobagyi GN, Buzdar AU, Theriault RL et al. (2000) Randomized trial of high-dose chemotherapy und blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92: 225–233PubMedCrossRef
17.
Zurück zum Zitat Leonard RC, Lind M, Twelves C et al. (2004) Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 96: 1076–1083PubMedCrossRef Leonard RC, Lind M, Twelves C et al. (2004) Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 96: 1076–1083PubMedCrossRef
18.
Zurück zum Zitat Lotz JP, Curlé H, Janvier M et al. (2005) High dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41: 71–80PubMedCrossRef Lotz JP, Curlé H, Janvier M et al. (2005) High dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41: 71–80PubMedCrossRef
19.
Zurück zum Zitat Nitz UA, Mohrmann S, Fischer J et al. (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366: 1935–1944PubMedCrossRef Nitz UA, Mohrmann S, Fischer J et al. (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366: 1935–1944PubMedCrossRef
20.
Zurück zum Zitat Peters WP, Ross M, Vredenburgh J (1993) High-dose chemotherapy und autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132–1143PubMed Peters WP, Ross M, Vredenburgh J (1993) High-dose chemotherapy und autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132–1143PubMed
21.
Zurück zum Zitat Peters WP, Rosner G, Vredenburgh J et al. (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23: 2191–2200PubMedCrossRef Peters WP, Rosner G, Vredenburgh J et al. (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23: 2191–2200PubMedCrossRef
22.
Zurück zum Zitat Petros WP, Hopkins PJ, Spruill S et al. (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer J Clin Oncol 23: 6117–6125 Petros WP, Hopkins PJ, Spruill S et al. (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer J Clin Oncol 23: 6117–6125
23.
Zurück zum Zitat Roche H, Pouillart P, Meyer N et al. (2001) Adjuvant High Dose Chemotherapy Improves Early Outcome for High Risk (N>7) Breast Cancer Patients: The Pegase 01 Trial. Proc Am Soc Clin Oncol: Abstract 102 Roche H, Pouillart P, Meyer N et al. (2001) Adjuvant High Dose Chemotherapy Improves Early Outcome for High Risk (N>7) Breast Cancer Patients: The Pegase 01 Trial. Proc Am Soc Clin Oncol: Abstract 102
24.
Zurück zum Zitat Roche H, Viens P, Lotz JP et al. (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10: 42–47PubMed Roche H, Viens P, Lotz JP et al. (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10: 42–47PubMed
25.
Zurück zum Zitat Rodenhuis S, Richel DJ, Van der Wall E et al. (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515–521PubMedCrossRef Rodenhuis S, Richel DJ, Van der Wall E et al. (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515–521PubMedCrossRef
26.
Zurück zum Zitat Rodenhuis S, Bontenbal M, Beex LVAM et al. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7–15PubMedCrossRef Rodenhuis S, Bontenbal M, Beex LVAM et al. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7–15PubMedCrossRef
27.
Zurück zum Zitat Rodenhuis S, Bontenbal M, van Hoesel QG et al.; Netherlands Working Party on Autologous Transplantation in Solid Tumours (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17: 588–596PubMedCrossRef Rodenhuis S, Bontenbal M, van Hoesel QG et al.; Netherlands Working Party on Autologous Transplantation in Solid Tumours (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17: 588–596PubMedCrossRef
28.
Zurück zum Zitat Schmid P, Schippinger W, Nitsch T et al. (2005) Up front tandem high-dose chemotherapy compared to standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432–440PubMedCrossRef Schmid P, Schippinger W, Nitsch T et al. (2005) Up front tandem high-dose chemotherapy compared to standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432–440PubMedCrossRef
29.
Zurück zum Zitat Stadtmauer EA, O’Neill A, Goldstein LJ et al. (2000) Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoetic Stem-Cell Transplantation for Metastatic Breast Cancer. N Engl J Med 324: 1069–1076CrossRef Stadtmauer EA, O’Neill A, Goldstein LJ et al. (2000) Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoetic Stem-Cell Transplantation for Metastatic Breast Cancer. N Engl J Med 324: 1069–1076CrossRef
30.
Zurück zum Zitat Stadtmauer EA, O’Neill A, Goldstein LJ (2002) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous stemm-cell transplantation for metastatic breast cancer: 5-year update of the „Philadelphia“ Trial (PBT-1). Proc Am Soc Clin Oncol 21: Abstract 169 Stadtmauer EA, O’Neill A, Goldstein LJ (2002) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous stemm-cell transplantation for metastatic breast cancer: 5-year update of the „Philadelphia“ Trial (PBT-1). Proc Am Soc Clin Oncol 21: Abstract 169
31.
Zurück zum Zitat Tallman MS, Gray R, Robert NJ et al. (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349: 17–26PubMedCrossRef Tallman MS, Gray R, Robert NJ et al. (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349: 17–26PubMedCrossRef
32.
Zurück zum Zitat Tanner M, Isola J, Wiklund T et al. (2006) Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Results From the Randomized Scandinavian Breast Group Trial 9401. J Clin Oncol [Epub ahead of print] Tanner M, Isola J, Wiklund T et al. (2006) Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Results From the Randomized Scandinavian Breast Group Trial 9401. J Clin Oncol [Epub ahead of print]
33.
Zurück zum Zitat Tokuda Y, Tajima T, Narabayashi M et al. (2001) Randomized phase III study of high-dose chemotherapy with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan clinical oncology group (JCOG9208). Proc Am Soc Clin Oncol: Abstract 148 Tokuda Y, Tajima T, Narabayashi M et al. (2001) Randomized phase III study of high-dose chemotherapy with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan clinical oncology group (JCOG9208). Proc Am Soc Clin Oncol: Abstract 148
34.
Zurück zum Zitat Vredenburgh JJ, Coniglio D, Broadwater G et al. (2006) Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12: 195–203PubMedCrossRef Vredenburgh JJ, Coniglio D, Broadwater G et al. (2006) Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12: 195–203PubMedCrossRef
35.
Zurück zum Zitat Vredenburgh JJ, Madan B, Coniglio D et al. (2006) A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant Apr 24 (published ahead online) Vredenburgh JJ, Madan B, Coniglio D et al. (2006) A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant Apr 24 (published ahead online)
36.
Zurück zum Zitat Weiss RB, Rifkin RM, Stewart FM et al. (2000) High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 355: 999–1003PubMedCrossRef Weiss RB, Rifkin RM, Stewart FM et al. (2000) High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 355: 999–1003PubMedCrossRef
37.
Zurück zum Zitat Weiss RB, Gill GG, Hudis CA (2001) An on-site audit of the south african trial of high-dose chemotherapy for metastatic breast cancer und associated publications. J Clin Oncol 19: 2771–2777PubMed Weiss RB, Gill GG, Hudis CA (2001) An on-site audit of the south african trial of high-dose chemotherapy for metastatic breast cancer und associated publications. J Clin Oncol 19: 2771–2777PubMed
38.
Zurück zum Zitat Zander AR, Kröger N, Schmoor C et al. (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22: 2273–2283PubMedCrossRef Zander AR, Kröger N, Schmoor C et al. (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22: 2273–2283PubMedCrossRef
Metadaten
Titel
Hochdosischemotherapie beim Mammakarzinom
verfasst von
Dr. P. Schmid
Publikationsdatum
01.06.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1090-y

Weitere Artikel der Ausgabe 5/2007

Der Onkologe 5/2007 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.